Oral Therapy Considerations for the Management of Myelodysplastic Syndromes (MDS)

A panel of experts discuss the complex nature of myelodysplastic syndromes and concurrent subclassifications.

Shared insight on how to best educate patients and caregivers on the broad nature of myelodysplastic syndromes.

Expert perspectives on the changes in MDS subclassifications as understandings of the disease have evolved.

Practical perspectives on how to communicate MDS subclassifications with affected patients and caregivers.

Experts consider shortcomings in the identification and management of myelodysplastic syndromes.

Reflections on the historical use of ESAs and blood transfusions to treat patients with myelodysplastic syndromes.

A brief review of disease and patient factors that influence the selection of therapy for myelodysplastic syndromes.

Panelists share insight on therapeutic goals when treating patients with myelodysplastic syndromes.

Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS.

Shared insight on the historical and current use of hypomethylating agents in patients with myelodysplastic syndromes.

Perspectives on the use of oral HMA therapy in higher-risk myelodysplastic syndromes, and how this has improved patient care.

Practical considerations for managing patient adherence on an oral therapy for higher-risk myelodysplastic syndromes.

Experts reflect on interchangeability between oral and intravenous therapy in patients with higher-risk myelodysplastic syndromes.

Panelists look toward the future management of myelodysplastic syndromes with respect to novel agents and treatment pathways.